In the increasingly cost-contained world of medical device market access, Payers (including ministries of health, insurers private & public, hospitals and local governments) are seeking to justify investment in new medical technologies. Health Technology Assessment (HTA) agencies are now widely spreads across Europe assess new technologies and interventions not only on the grounds of clinical effectiveness, but also based on cost-effectiveness, cost-utility and cost-benefit, to ensure the payers’ limited funds are well invested. This HTA and value demonstration requirement has evolved the “commercialisation” landscape of medical devices across the world and this next barrier is one that all medical device companies seeking to gain reimbursement and approval from payers and tendering bodies, need to overcome.

The variety of commercial channels, customers and payers within the medical device space is as diverse as the different business models being used for the different product types (e.g. Imaging Vs Surgical products) and only increases the complexity and specificity of the “value message” which needs to well-delivered, in order to ensure an optimal outcome. This three-day event is the “must-attend” event for all senior directors at medical device companies who are looking to enhance market access for their products.

The first day will feature Europe’s leading payers, HTAs and market access KOLs discussing what they want to see from medical device manufacturers bringing new products to the market and will be a perfect opportunity to engage these key stakeholders. The second day of the event will contrast market access strategies for medical devices in key markets to enable market access and product managers to sequence and prioritise their product launch.

The different stakeholders involved in each market access process and the varying ways to engage them and demonstrate “value” for your technologies will be show from leading companies in the field for you to learn and benchmark from. Participants will leave this event armed with real-life, best practice examples of what is working and not working for your specific product type; what Payers and HTAs consider as essential and “nice to have” information to create “value”; and will have established relationships with the peers from the industry as well as influential decision-makers & KOLs in this sector. We look forward to meeting you in Zürich!

Request agenda here for complete speaker list

Payers & HTA Agencies

Chief Innovation Officer
Catalan Agency for Health Quality and Assessment – AquAS

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Vice President - Strategic Procurement and Supply of Pharmaceuticals and Medical devices
Amgros, Procurement Service for Regional Authorities, Denmark

Scientific Adviser
RIZIV-INAMI, Belgium

Director
Umbria Region Health Authority, Italy

Head of the Department of Medicines, Therapeutic Appliances & Remedies Product- and Billing Management Division
DAK–Gesundheit, (Leading German statutory health insurance)

Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)

Erasmus University Rotterdam, Netherlands

Former Chief Innovation Officer
America’s Health Insurance Plans (AHIP), USA
 

Industry Experts

Vice President Market Access
Medtronic, USA

Senior Director, Global Health Economics & Reimbursement
Edwards Lifesciences, USA

Senior Director Strategic Affairs, Payer Pricing & Tender Strategy
Johnson & Johnson Diabetes Care, Switzerland

Senior Director, Health Economics & Payment Policy
Stryker, USA

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Director, Government Affairs and Access Policy EMEA, Canada & LATAM
Edwards Lifesciences, France

Director Market Access and Health Economics, EMEA
Abbott Vascular, Belgium

Director Health Economics & Market Access DACH
Johnson & Johnson Medical, Germany

Director, Market Access & Economic Policies
MedTech Europe, Belgium

Vice-President Market Access and Commercial Excellence
Merit Medical Systems, Netherlands

Director Payers & Health Economics
Coloplast, Germany

Director, Market Access – EMEA
Teleflex, Belgium

Market and Business Insights Manager Europe and Canada
Smith & Nephew, Switzerland

Manager Strategic Reimbursement
Zoll CMS, Germany

Senior Health Economics Manager
Arthrex, Denmark

Market Sales Leader CEE
Philips Image Guided Therapy-Devices, Poland
 

Experienced Solution Provider

Founder & CEO
MTRC – European Med Tech and IVD Reimbursement Consulting

Request agenda here for complete speaker list

Pictures from recent MedTech Access Leaders Forum. Imagine being there...

Global healthcare systems are evolving daily. At a time of increased health economic reform, ageing populations and budget austerity, leaders in medical technology look to achieve optimal market access and commercialization of their products. As payers worldwide demand more value for money on the medical devices they fund, the importance of achieving patient access by demonstrating cost effectiveness and enhanced health outcomes is of the utmost importance. With payers in both developed and developing countries under extreme budgetary pressure, we will provide a platform for attendees to examine how health technologies are assessed, tough decisions are made and how we define “value”. This exclusive forum is the opportunity to meet and network with a broad spectrum of senior representatives who wish to encourage innovation whilst managing a limited budget.

SPEAKER LIST - DAY 1

Chief Innovation Officer
Catalan Agency for Health Quality and Assessment – AquAS

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Vice President - Strategic Procurement and Supply of Pharmaceuticals and Medical devices
Amgros, Procurement Service for Regional Authorities, Denmark

Scientific Adviser
RIZIV-INAMI, Belgium

Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)

Erasmus University Rotterdam, Netherlands

Director
Umbria Region Health Authority, Italy

Head of the Department of Medicines, Therapeutic Appliances & Remedies Product- and Billing Management Division
DAK–Gesundheit, (Leading German statutory health insurance)

Vice President Market Access
Medtronic, USA

 

Medical device firms are increasingly under pressure from payers, HTA agencies, healthcare providers and other stakeholders to provide real evidence of their product’s benefit. Increasingly, especially when a technology is expensive, the CE Mark alone is no longer sufficient to gain market access. Robust health economic evidence demonstrating the clinical and economic value of a device is either becoming mandatory, or at least can be a source or competitive advantage to differentiate apparently similar products. Evidence can still be generated from scientific publications, but on top of this, sophisticated and expensive clinical trials and even real-world studies are now being designed and implemented. Getting the trial design right from the beginning is essential, so that the right research questions are being asked and robust methodologies are used to demonstrate improved health outcomes. Protocols must also be operationally feasible to ensure not just messy data is developed, but real evidence so that payers can gain insights into the value and make better reimbursement decisions. This stream will detail  how clinical, real-world, economic and scientific publication data sources can be integrated to prepare a sophisticated value dossier to demonstrate value to payers and other key stakeholders.

SPEAKER LIST - DAY 2

Senior Director Strategic Affairs, Payer Pricing & Tender Strategy
Johnson & Johnson Diabetes Care, Switzerland

Director Market Access and Health Economics, EMEA
Abbott Vascular, Belgium

Senior Director, Health Economics & Payment Policy
Stryker, USA

Director Payers & Health Economics
Coloplast, Germany

Director, Market Access – EMEA
Teleflex, Belgium

Manager Strategic Reimbursement
Zoll CMS, Germany

Director, Market Access & Economic Policies
MedTech Europe, Belgium

Director, Government Affairs and Access Policy EMEA, Canada & LATAM
Edwards Lifesciences, France

Director Health Economics & Market Access DACH
Johnson & Johnson Medical, Germany

Market and Business Insights Manager Europe and Canada
Smith & Nephew, Switzerland

 

SPEAKER LIST - DAY 3

Senior Director, Global Health Economics & Reimbursement
Edwards Lifesciences, USA

Former Chief Innovation Officer
America’s Health Insurance Plans (AHIP), USA

Vice-President Market Access and Commercial Excellence
Merit Medical Systems, Netherlands

Senior Health Economics Manager
Arthrex, Denmark

Market Sales Leader CEE
Philips Image Guided Therapy-Devices, Poland

Founder & CEO
MTRC – European Med Tech and IVD Reimbursement Consulting

 

Device manufacturers & distributors:
Marketing, Market-access, Business Development, Country Managers, Health Economics, Pricing & Reimbursement, Government & Stakeholder Relations, Regulatory Affairs

Stakeholders:
Health Plans & Insurers, Payers, Health Technology Assessors, Hospitals, Health Ministry, Regulatory Agencies, Independent Health Economists, Academics, Physicians and Patient Groups

Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Global and Regional Heads, Independent Academics, Health Economists

Event Partners

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Share with Colleagues